#nucmed — Public Fediverse posts
Live and recent posts from across the Fediverse tagged #nucmed, aggregated by home.social.
-
Struggling to translate a #radiopharmaceuticals 101 talk from English to Spanish.
It's one thing to shoot the breeze, but a whole other thing to speak on "quelantes," "radionúclidos metálicos," "imagenología" and "marcadores radioactivos" 😬😅
-
Struggling to translate a #radiopharmaceuticals 101 talk from English to Spanish.
It's one thing to shoot the breeze, but a whole other thing to speak on "quelantes," "radionúclidos metálicos," "imagenología" and "marcadores radioactivos" 😬😅
-
Struggling to translate a #radiopharmaceuticals 101 talk from English to Spanish.
It's one thing to shoot the breeze, but a whole other thing to speak on "quelantes," "radionúclidos metálicos," "imagenología" and "marcadores radioactivos" 😬😅
-
🚨 Fellow #radiotheranostics nerds 🚨
Prof. Tim Witney and I are launching a Collection focused on this very topic for NPJ Imaging
Please considering submitting! Site is live!
-
🚨 Fellow #radiotheranostics nerds 🚨
Prof. Tim Witney and I are launching a Collection focused on this very topic for NPJ Imaging
Please considering submitting! Site is live!
-
🚨 Fellow #radiotheranostics nerds 🚨
Prof. Tim Witney and I are launching a Collection focused on this very topic for NPJ Imaging
Please considering submitting! Site is live!
-
🚨Hot off the presses🚨
Colleagues in Netherlands & Germany evaluated 68Ga-peptide specific to GPC3 in patients w #HCC.
✅Uptake in HCC and hepatoblastoma lesions
💡Heterogeneity of GPC3 expression in HCC
💡Gastric fundus uptake, but likely cleared over time -
🚨Hot off the presses🚨
Colleagues in Netherlands & Germany evaluated 68Ga-peptide specific to GPC3 in patients w #HCC.
✅Uptake in HCC and hepatoblastoma lesions
💡Heterogeneity of GPC3 expression in HCC
💡Gastric fundus uptake, but likely cleared over time -
🚨Hot off the presses🚨
Colleagues in Netherlands & Germany evaluated 68Ga-peptide specific to GPC3 in patients w #HCC.
✅Uptake in HCC and hepatoblastoma lesions
💡Heterogeneity of GPC3 expression in HCC
💡Gastric fundus uptake, but likely cleared over time -
🚨New #radiopharmaceuticals imaging study out of The Netherlands🚨
HER2 PET can identify metastatic breast cancer with IHC-defined HER2-negative and low lesions.
PET can define the heterogeneity of target expression throughout a patient.
-
🚨New #radiopharmaceuticals imaging study out of The Netherlands🚨
HER2 PET can identify metastatic breast cancer with IHC-defined HER2-negative and low lesions.
PET can define the heterogeneity of target expression throughout a patient.
-
🚨New #radiopharmaceuticals imaging study out of The Netherlands🚨
HER2 PET can identify metastatic breast cancer with IHC-defined HER2-negative and low lesions.
PET can define the heterogeneity of target expression throughout a patient.
-
Happy galley proofs day to those who celebrate!!!
Stay tuned for a new paper that describes not one but *two* to methods to yield site-specifically conjugated small proteins labeled with [18F]AlF for fluorine-18-based positron emission tomograpy (PET) imaging.
-
Happy galley proofs day to those who celebrate!!!
Stay tuned for a new paper that describes not one but *two* to methods to yield site-specifically conjugated small proteins labeled with [18F]AlF for fluorine-18-based positron emission tomograpy (PET) imaging.
-
Happy galley proofs day to those who celebrate!!!
Stay tuned for a new paper that describes not one but *two* to methods to yield site-specifically conjugated small proteins labeled with [18F]AlF for fluorine-18-based positron emission tomograpy (PET) imaging.
-
It’s certainly a bit anachronistic, but there’s something to be said for seeing your work in print.
-
It’s certainly a bit anachronistic, but there’s something to be said for seeing your work in print.
-
It’s certainly a bit anachronistic, but there’s something to be said for seeing your work in print.
-
In this era of divisiveness, it is refreshing to have societies with interests and expertise in #radiopharmaceuticals therapy come together.
-
In this era of divisiveness, it is refreshing to have societies with interests and expertise in #radiopharmaceuticals therapy come together.
-
In this era of divisiveness, it is refreshing to have societies with interests and expertise in #radiopharmaceuticals therapy come together.
-
-
-
-
Our PhD student Stan *crushed* his presentation and Q&A at #ASTRO23
So lucky to get to work with such amazing trainees at the NCI!
Fun fact: Stan has already gotten an invite to present his science at ASTRO--an achievement that's eluded me thus far!
-
Our PhD student Stan *crushed* his presentation and Q&A at #ASTRO23
So lucky to get to work with such amazing trainees at the NCI!
Fun fact: Stan has already gotten an invite to present his science at ASTRO--an achievement that's eluded me thus far!
-
Our PhD student Stan *crushed* his presentation and Q&A at #ASTRO23
So lucky to get to work with such amazing trainees at the NCI!
Fun fact: Stan has already gotten an invite to present his science at ASTRO--an achievement that's eluded me thus far!
-
Excellent editorial by experts in #radiopharmaceuticals therapy regarding feasibility and need for personalized/individualized dosimetry to optimize therapeutic index in patients.
https://doi.org/10.1007/s00259-023-06420-z
Closing statement certainly resonates!
-
Excellent editorial by experts in #radiopharmaceuticals therapy regarding feasibility and need for personalized/individualized dosimetry to optimize therapeutic index in patients.
https://doi.org/10.1007/s00259-023-06420-z
Closing statement certainly resonates!
-
Excellent editorial by experts in #radiopharmaceuticals therapy regarding feasibility and need for personalized/individualized dosimetry to optimize therapeutic index in patients.
https://doi.org/10.1007/s00259-023-06420-z
Closing statement certainly resonates!
-
RT @officialEANM: Curious about #NucMed challenges on research infrastructures & nuclear competences?
Check out @EU_ScienceHub report on Third 🇪🇺 High Level Nuclear Roundtable on Medical Applications
📝Roadblocks preventing technological advances from reaching patients
👉https://publications.jrc.ec.europa.eu/repository/handle/JRC133078 https://t.co/B5Hy6yvbZE
🐦🔗: https://n.respublicae.eu/EU_ScienceHub/status/1654105540664999937
-
RT @officialEANM: Curious about #NucMed challenges on research infrastructures & nuclear competences?
Check out @EU_ScienceHub report on Third 🇪🇺 High Level Nuclear Roundtable on Medical Applications
📝Roadblocks preventing technological advances from reaching patients
👉https://publications.jrc.ec.europa.eu/repository/handle/JRC133078 https://t.co/B5Hy6yvbZE
🐦🔗: https://n.respublicae.eu/EU_ScienceHub/status/1654105540664999937
-
RT @officialEANM: Curious about #NucMed challenges on research infrastructures & nuclear competences?
Check out @EU_ScienceHub report on Third 🇪🇺 High Level Nuclear Roundtable on Medical Applications
📝Roadblocks preventing technological advances from reaching patients
👉https://publications.jrc.ec.europa.eu/repository/handle/JRC133078 https://t.co/B5Hy6yvbZE
🐦🔗: https://n.respublicae.eu/EU_ScienceHub/status/1654105540664999937
-
Lots of folks in #nucmed and #radonc are interested in launching their own #radiopharmaceuticals ☢️therapy program, but not sure where to start.
If you're in this camp, you're in luck!🍀
@[email protected] and the team @[email protected] put together this comprehensive guide!
👇👇👇
-
Lots of folks in #nucmed and #radonc are interested in launching their own #radiopharmaceuticals ☢️therapy program, but not sure where to start.
If you're in this camp, you're in luck!🍀
@[email protected] and the team @[email protected] put together this comprehensive guide!
👇👇👇
-
Lots of folks in #nucmed and #radonc are interested in launching their own #radiopharmaceuticals ☢️therapy program, but not sure where to start.
If you're in this camp, you're in luck!🍀
@[email protected] and the team @[email protected] put together this comprehensive guide!
👇👇👇
-
Lots of folks in #nucmed and #radonc are interested in launching their own #radiopharmaceuticals ☢️therapy program, but not sure where to start.
If you're in this camp, you're in luck!🍀
@[email protected] and the team @[email protected] put together this comprehensive guide!
👇👇👇
-
Friday afternoon resubmission ftw!
-
Friday afternoon resubmission ftw!
-
Friday afternoon resubmission ftw!
-
TFW you submitted a grant review!
#radonc #nucmed #MedMastodon #academia #medtwitter #academictwitter
-
TFW you submitted a grant review!
#radonc #nucmed #MedMastodon #academia #medtwitter #academictwitter
-
TFW you submitted a grant review!
#radonc #nucmed #MedMastodon #academia #medtwitter #academictwitter
-
Press release on PSMAfore trial, a ph3 study of pts with mCRPC randomized to switch of androgen receptor pathway inhibitor or 177Lu-PSMA tx.
✅1° endpt of sig improvement in radiographic PFS met
✅ no unexpected safety findings#Radiopharmaceuticals #Oncology #NucMed #RadOnc #ProstateCancer
-
Press release on PSMAfore trial, a ph3 study of pts with mCRPC randomized to switch of androgen receptor pathway inhibitor or 177Lu-PSMA tx.
✅1° endpt of sig improvement in radiographic PFS met
✅ no unexpected safety findings#Radiopharmaceuticals #Oncology #NucMed #RadOnc #ProstateCancer
-
Press release on PSMAfore trial, a ph3 study of pts with mCRPC randomized to switch of androgen receptor pathway inhibitor or 177Lu-PSMA tx.
✅1° endpt of sig improvement in radiographic PFS met
✅ no unexpected safety findings#Radiopharmaceuticals #Oncology #NucMed #RadOnc #ProstateCancer
-
Press release on PSMAfore trial, a ph3 study of pts with mCRPC randomized to switch of androgen receptor pathway inhibitor or 177Lu-PSMA tx.
✅1° endpt of sig improvement in radiographic PFS met
✅ no unexpected safety findings#Radiopharmaceuticals #Oncology #NucMed #RadOnc #ProstateCancer
-
Can anyone help me understand the continued #radiopharmaceuticals work with girentuximab given that a phase 2 published in 2016 was underwhelming? 🤔🤷🏽♂️
I’m surely missing something.
https://www.sciencedirect.com/science/article/pii/S030228381501204X
-
Can anyone help me understand the continued #radiopharmaceuticals work with girentuximab given that a phase 2 published in 2016 was underwhelming? 🤔🤷🏽♂️
I’m surely missing something.
https://www.sciencedirect.com/science/article/pii/S030228381501204X
-
Can anyone help me understand the continued #radiopharmaceuticals work with girentuximab given that a phase 2 published in 2016 was underwhelming? 🤔🤷🏽♂️
I’m surely missing something.
https://www.sciencedirect.com/science/article/pii/S030228381501204X
-
Can anyone help me understand the continued #radiopharmaceuticals work with girentuximab given that a phase 2 published in 2016 was underwhelming? 🤔🤷🏽♂️
I’m surely missing something.
https://www.sciencedirect.com/science/article/pii/S030228381501204X
-
Nice! This recent paper in JACS might be of interest then: https://pubs.acs.org/doi/full/10.1021/jacs.2c08438